Pharmacogenomic approaches that may guide preeclampsia therapy

Pharmacogenomics

Volumn 14, Issue 6, 2013, Pages 591-593

  Luizon, Marcelo R ^a   Sandrim, Valeria C ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

antihypertensive therapy; epigenetics; epistasis; pharmacogenomics; preeclampsia

Indexed keywords

ATORVASTATIN; ENDOGLIN; HYDRALAZINE; LABETALOL; METHYLDOPA; NIFEDIPINE; NITRIC OXIDE; VASCULOTROPIN RECEPTOR 1;

CACNA1A GENE; CYP3A5 GENE; DISEASE MARKER; DNA POLYMORPHISM; ENOS GENE; EPIGENETICS; EPISTASIS; FLT 1 GENE; GENE; HUMAN; MMP9 GENE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREECLAMPSIA; REVIEW; TREATMENT OUTCOME; VEGF GENE; VEGFR 1 GENE; VEGFR 2 GENE;

ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; PHARMACOGENETICS; PRE-ECLAMPSIA; PREGNANCY;

EID: 84875973410     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.23     Document Type: Review

References (24)

1. Lewis G. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer-2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. Lewis G (Ed.). CEMACH, London, UK (2007).
2. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 51(4), 960-969 (2008). (Pubitemid 351398945)
3. Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J. 10(1), 40-45 (2010).
4. Williams PJ, Morgan L. The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. Pharmgenomics Pers. Med. 5, 37-51 (2012).
5. Sadee W., Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect. Pharmacogenomics 12(5), 675-680 (2011).
6. Palei AC, Sandrim VC, Amaral LM et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J. 12(6), 489-498 (2012).
7. Bremer T, Man A, Kask K, Diamond C. CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 7(3), 271-279 (2006).
8. Haas DM, Quinney SK, Clay JM et al. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am. J. Perinatol. doi:10.1055/s-0032-1323590 (2012) (Epub ahead of print).
9. Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet. Gynecol. 105(1), 182-192 (2005). (Pubitemid 40189930)
10. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 52(2), 402-407 (2008).
11. Sandrim VC, Palei AC, Sertorio JT, Cavalli RC, Duarte G, Tanus-Santos JE. Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. Mol. Hum. Reprod. 16(7), 506-510 (2010).
12. Sandrim VC, Palei AC, Cavalli RC et al. eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 9(10), 1467-1473 (2008).
13. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic. Biol. Med. 41(7), 1044-1049 (2006). (Pubitemid 44331568)
14. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb. Res. 127(Suppl. 3), S72-S75 (2011).
15. Williams PJ, Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 25(4), 405-417 (2011).
16. Luizon MR, Sandrim VC, Palei AC et al. Epistasis among eNOS, MMP-9 and VEGF maternal genotypes in hypertensive disorders of pregnancy. Hypertens. Res. 35(9), 917-921 (2012).
17. Founds SA, Shi H, Conley YP, Jeyabalan A, Roberts JM, Lyons-Weiler J. Variations in discovery-based preeclampsia candidate genes. Clin. Transl. Sci. 5(4), 333-339 (2012).
18. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111(5), 649-658 (2003). (Pubitemid 36278583)
19. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res. 22(9), 1748-1759 (2012).
20. Chelbi ST, Vaiman D. Genetic and epigenetic factors contribute to the onset of preeclampsia. Mol. Cell. Endocrinol. 282(1-2), 120-129 (2008).
21. Nelissen EC, Van Montfoort AP, Dumoulin JC, Evers JL. Epigenetics and the placenta. Hum. Reprod. Update 17(3), 397-417 (2011).
22. Dunham I, Kundaje A, Aldred SF et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57-74 (2012).
23. Glubb DM, Innocenti F. Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand? Pharmacogenomics 14(1), 1-4 (2013).
24. Wold B, Myers RM. Sequence census methods for functional genomics. Nat. Methods 5(1), 19-21 (2008).